Hims & Hers shares slide 5%

Telehealth stocks move on stories, but this one is moving on regulation. Hims & Hers fell more than 5% on Tuesday, April 29, to close at $27.91. The immediate selloff looks small compared with the stock’s bigger swings, but the reason matters — investors are still trying to figure out what Hims looks like after the easy phase of the GLP-1 boom ends. (finance.yahoo.com) ### Why did the stock drop now? There was no single bombshell on April 29. The move landed as investors kept digesting Hims’ March weight-loss reset, a fresh proxy filing ahead of its June 11 annual meeting, and the fact that first-quarter 2026 results are due on May 11. Basically, the market is in a “show me” phase now — less excitement about the category, more fo(finance.yahoo.com)get harder to sell at scale. (sec.gov) ### What changed in weight loss? Hims used to benefit from a weird window in the market. Brand-name GLP-1 drugs were hard to get, shortages opened the door to compounding, and telehealth platforms could offer alternatives quickly. That window narrowed when the FDA determined the semaglutide injection shortage was resolved in Feb(sec.gov)date for certain state-licensed compounders. Once that happened, the old growth playbook got shakier. (fda.gov) ### So what is Hims doing instead? In March, Hims announced a strategic shift. The company said it would work with Novo Nordisk, expand access to FDA-approved GLP-1 options, and keep compounded semaglutide available only on a limited scale. A couple of weeks later, it said Novo Nordisk’s FDA-approved GLP-1 lineup was available through the platform, including Wegovy and t(fda.gov) marketing of compounded products and toward acting more like a distribution and care layer on top of branded drugs. (investors.hims.com) ### Why does that make investors nervous? Because branded GLP-1s are not the same business as compounded GLP-1s. The branded route may be more durable and cleaner from a regulatory standpoint, but margins can look different, supply can still be a constraint, and Hims has less(investors.hims.com)nvestors now need proof those advantages survive the transition. (investors.hims.com) ### Is the business otherwise holding up? The core company has been growing fast. Hims reported $1.5 billion in 2024 revenue, up 69% year over year, with 2.2 million subscribers. It then guided for 2025 revenue of $2.3 billion to $2.4 billion. So this is not a story about a collapsing business. It is a story about whether one of its hottest categories can stay hot under tighter rules. (investors.hims.com) ### What are investors watching next? May 11 is the next real checkpoint. Hims will report first-quarter 2026 results after the market closes that day, then hold a call at 5 p.m. ET. Investors will want details on weight-loss mix, branded GLP-1 uptake, customer demand, and whether the Novo partnership is helping replace what tighter compounding rules took away. (investors.hims.com) ### Bottom line? The 5% drop was really a vote of caution. Hims is trying to prove it can turn a shortage-era opportunity into a steadier long-term business. If May 11 shows that pivot is working, this slide may look like noise. If not, investors will keep treating every GLP-1 headline as a threat.